Benedito A. Carneiro

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Andrès M.R. Cervantes · 2 shared papers, 2025–2026 · strength 0.41
   • Paper Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial. DOI 10.1038/s41591-026-04327-4↗
   • Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122↗
2. Devalingam Mahalingam · 2 shared papers, 2025–2026 · strength 0.41
   • Paper Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial. DOI 10.1038/s41591-026-04327-4↗
   • Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122↗
3. Andrew L. Coveler · 2 shared papers, 2025–2026 · strength 0.41
   • Paper Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial. DOI 10.1038/s41591-026-04327-4↗
   • Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122↗
4. Vaibhav Sahai · 2 shared papers, 2025–2026 · strength 0.41
   • Paper Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial. DOI 10.1038/s41591-026-04327-4↗
   • Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122↗
5. Mary F. Mulcahy · 2 shared papers, 2025–2026 · strength 0.41
   • Paper Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial. DOI 10.1038/s41591-026-04327-4↗
   • Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122↗
6. Rachna T. Shroff · 1 shared paper, 2026 · strength 0.22
   • Paper Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial. DOI 10.1038/s41591-026-04327-4↗
7. Noelle K. LoConte · 1 shared paper, 2026 · strength 0.22
   • Paper Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial. DOI 10.1038/s41591-026-04327-4↗
8. Anne Ploquin · 1 shared paper, 2026 · strength 0.22
   • Paper Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial. DOI 10.1038/s41591-026-04327-4↗
9. Petr Kavan · 1 shared paper, 2026 · strength 0.22
   • Paper Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial. DOI 10.1038/s41591-026-04327-4↗
10. Ryan Michael Carr · 1 shared paper, 2026 · strength 0.22
    • Paper Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial. DOI 10.1038/s41591-026-04327-4↗
11. Tanios Bekaii‐Saab · 1 shared paper, 2026 · strength 0.22
    • Paper Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial. DOI 10.1038/s41591-026-04327-4↗
12. Simon Pernot · 1 shared paper, 2026 · strength 0.22
    • Paper Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial. DOI 10.1038/s41591-026-04327-4↗
13. Charles D. Lopez · 1 shared paper, 2026 · strength 0.22
    • Paper Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial. DOI 10.1038/s41591-026-04327-4↗
14. Alexander Grenander Raufi · 1 shared paper, 2025 · strength 0.19
    • Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122↗
15. Steven Francis Powell · 1 shared paper, 2025 · strength 0.19
    • Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122↗
16. Marisol Huerta · 1 shared paper, 2025 · strength 0.19
    • Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122↗
17. Ludimila L. Cavalcante · 1 shared paper, 2025 · strength 0.19
    • Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122↗
18. Anwaar Saeed · 1 shared paper, 2025 · strength 0.19
    • Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122↗
19. Jordan D. Berlin · 1 shared paper, 2025 · strength 0.19
    • Paper Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in pre… DOI 10.1016/j.esmoop.2025.105122↗
20. Aakash Jhaveri · 1 shared paper, 2021 · strength 0.12
    • Paper Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenogr… DOI 10.1080/15384047.2021.1976567↗
21. Wafik S. El‐Deiry · 1 shared paper, 2021 · strength 0.12
    • Paper Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenogr… DOI 10.1080/15384047.2021.1976567↗
22. Howard P. Safran · 1 shared paper, 2021 · strength 0.12
    • Paper Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenogr… DOI 10.1080/15384047.2021.1976567↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.